Pharmaceuticals, Biotechnology & Life Sciences

Johnson & Johnson’s $1.2 billion Firefly Bio deal and Sail Biomedicines partnership boost oncology and CAR‑T portfolios, offering patent protection and high‑growth market access.

Biogen’s Q2 2026 results show modest revenue growth and a new earnings outlook, driven by Apellis acquisitions and strong Leqembi sales, hinting at a diversified future.

Roche Holding sees a 0.6% dip after RBI’s “Hold” downgrade, yet its strong R&D spend and value‑based strategy aim to keep Swiss pharma leaders ahead of rising Chinese competition.

Brazil’s ANVISA approves Sandoz’s Owozy® semaglutide— a pre‑filled, affordable diabetes drug poised to expand global access and boost Sandoz’s Brazilian portfolio.

Incyte’s Q2 2026 earnings boost revenue & earnings, driving stock to a 52‑week high thanks to Jakafi growth, Opzelura CMS gains and a strong pipeline outlook.

GSK’s 2026 Q2 report shows 14% specialty‑medicine growth, 8% vaccine boost, and a £1.9bn cost‑saving plan, positioning it for strong profit and future R&D success.

Argenx’s acquisition of Forte Biosciences boosts its autoimmune pipeline with the promising CD122 antibody FB102, offering a novel cytokine‑receptor approach to treat vitiligo and coeliac disease.

New Eisai‑Pfizer partnership will launch Nurtec® for acute & preventive migraine in Japan, backed by robust Phase‑3 efficacy, safety, and real‑world benefit data.

Vertex expands R&D in oncology & immunology, partners on a $250 M biopharma deal, boosting its $3.7 B pipeline and long‑term growth outlook.

United Therapeutics insider trades: Martine Rothblatt’s 10(b)(5) buys and sells show confidence in the firm’s pipeline and strategic liquidity management while keeping ownership stable.